X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (150) 150
Conference Proceeding (25) 25
Publication (14) 14
Book Review (13) 13
Book / eBook (10) 10
Dissertation (2) 2
Newspaper Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (83) 83
humans (69) 69
oncology (61) 61
female (54) 54
middle aged (34) 34
aged (31) 31
adult (30) 30
surgery (21) 21
chemotherapy (20) 20
ovarian cancer (20) 20
analysis (19) 19
cancer (19) 19
obstetrics & gynecology (19) 19
male (18) 18
ovarian neoplasms - drug therapy (17) 17
patients (15) 15
survival (14) 14
bevacizumab (13) 13
medical and health sciences (13) 13
medicin och hälsovetenskap (13) 13
aged, 80 and over (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
prospective studies (12) 12
research (12) 12
disease-free survival (11) 11
paclitaxel (11) 11
clinical medicine (10) 10
mortality (10) 10
drug therapy (9) 9
klinisk medicin (9) 9
medicine & public health (9) 9
mutation (9) 9
toxicity (9) 9
treatment outcome (9) 9
antineoplastic agents - therapeutic use (8) 8
care and treatment (8) 8
clinical trials (8) 8
follow-up studies (8) 8
medical research (8) 8
studies (8) 8
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer therapies (7) 7
carboplatin (7) 7
carcinoma (7) 7
combined modality therapy (7) 7
health aspects (7) 7
hematology, oncology and palliative medicine (7) 7
medicine (7) 7
neoplasm staging (7) 7
paclitaxel - administration & dosage (7) 7
pakistan (7) 7
pharmacology & pharmacy (7) 7
prognosis (7) 7
risk (7) 7
risk factors (7) 7
women (7) 7
young adult (7) 7
abridged index medicus (6) 6
carboplatin - administration & dosage (6) 6
diseases (6) 6
double-blind method (6) 6
gynecology (6) 6
medical informatics (6) 6
medicine, general & internal (6) 6
ovarian neoplasms - genetics (6) 6
ovarian neoplasms - pathology (6) 6
platinum (6) 6
research article (6) 6
adolescent (5) 5
animals (5) 5
biomedicine (5) 5
breast cancer (5) 5
breast neoplasms - drug therapy (5) 5
cancer and oncology (5) 5
cancer och onkologi (5) 5
cohort studies (5) 5
doxorubicin - administration & dosage (5) 5
doxorubicin - analogs & derivatives (5) 5
drug administration schedule (5) 5
endometrial cancer (5) 5
external-beam radiotherapy (5) 5
genetics (5) 5
guidelines (5) 5
health (5) 5
hospitals (5) 5
journal article (5) 5
maintenance therapy (5) 5
management (5) 5
medicine, experimental (5) 5
monitoring (5) 5
neutropenia (5) 5
outcomes (5) 5
ovarian neoplasms (5) 5
pharmacokinetics (5) 5
phase-iii trial (5) 5
polyethylene glycols - administration & dosage (5) 5
practice guidelines as topic (5) 5
relapse (5) 5
survival analysis (5) 5
thrombocytopenia (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 8, pp. 801 - 802
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 22, pp. 2154 - 2164
Among patients with platinum-sensitive, recurrent ovarian cancer, the use of niraparib, a PARP inhibitor, was associated with a significantly longer duration... 
TRIAL | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | MEDICINE, GENERAL & INTERNAL | SOLID TUMORS | BRCA MUTATION CARRIERS | NEGATIVE BREAST-CANCER | Humans | Middle Aged | Homologous Recombination | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Platinum Compounds - therapeutic use | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Germ-Line Mutation | Adult | Female | Maintenance Chemotherapy | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Bone Marrow - drug effects | Double-Blind Method | Kaplan-Meier Estimate | Disease-Free Survival | Piperidines - therapeutic use | Piperidines - adverse effects | Adolescent | Aged | Indazoles - adverse effects | Neoplasm Staging | Indazoles - therapeutic use | Care and treatment | Adenosine diphosphate | Research | Diagnosis | Patients | Health aspects | Ovarian cancer | Thrombocytopenia | Adenosine | Inhibitor drugs | Toxicity | Homologous recombination | Clinical trials | Poly(ADP-ribose) polymerase | Breast cancer | Cancer therapies | Survival | Ribose | Platinum | Bone marrow | Mutation | Drug therapy | Health risk assessment | Tumors | Neutropenia | Index Medicus | Abridged Index Medicus | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 928 - 936
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Risk groups | Body weight | Clinical trials | Survival | Angiogenesis | Chemotherapy | Womens health | Paclitaxel | Carboplatin | Vascular endothelial growth factor | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 78 - 89
Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,... 
Hematology, Oncology and Palliative Medicine | BIBF 1120 | DES CANCERS | INTERGROUP TRIAL | LABEL DOSE-ESCALATION | CISPLATIN | ONCOLOGY | BEVACIZUMAB | TRIPLE ANGIOKINASE INHIBITOR | CARBOPLATIN PLUS PACLITAXEL | III TRIAL | MAINTENANCE THERAPY | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Diarrhea - chemically induced | Cytoreduction Surgical Procedures | Indoles - administration & dosage | Young Adult | Peritoneal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Carcinoma - pathology | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Peritoneal Neoplasms - pathology | Double-Blind Method | Carcinoma - surgery | Peritoneal Neoplasms - surgery | Anemia - chemically induced | Carboplatin - administration & dosage | Fallopian Tube Neoplasms - pathology | Thrombocytopenia - chemically induced | Disease Progression | Disease-Free Survival | Indoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Fallopian Tube Neoplasms - surgery | Intention to Treat Analysis | Aged | Neoplasm Staging | Ovarian Neoplasms - surgery | Clinical trials | Chemotherapy | Hospitals | Growth factors | Cancer | Ovarian cancer | Index Medicus | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Cancer and Oncology | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2014, Volume 32, Issue 30, pp. 3374 - 3381
Journal Article
The Lancet Oncology, ISSN 1470-2045, 08/2018, Volume 19, Issue 8, pp. 1117 - 1125
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 5826 - 5826
Journal Article
Journal Article